{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Johnson & Johnson
Johnson & Johnson Hits New 52-Week High at $189.92, Showcasing Strong Growth
Johnson & Johnson achieved a new 52-week high of USD 189.92 on October 6, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a notable stock price increase over the past year, supported by solid financial metrics and a substantial market capitalization.
Johnson & Johnson Hits New 52-Week High at USD 189.78
Johnson & Johnson achieved a new 52-week high of USD 189.78 on October 3, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, with a solid market capitalization and favorable financial metrics, indicating effective resource management and profitability.
Johnson & Johnson Hits New 52-Week High at $186.55, Up 26.45%
Johnson & Johnson achieved a new 52-week high of USD 186.55 on October 1, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 26.45% growth over the past year, significantly outperforming the S&P 500, and maintains solid financial metrics.
Johnson & Johnson Hits New 52-Week High at $185.99
Johnson & Johnson achieved a new 52-week high of USD 185.99 on September 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 26.02% growth over the past year, with a market capitalization of USD 515.81 billion and a solid financial foundation.
Johnson & Johnson Hits Day High with Strong 3.18% Intraday Surge
Johnson & Johnson's stock has shown strong performance, significantly outperforming the S&P 500 over various time frames. The company maintains a robust financial position, characterized by a low Debt to EBITDA ratio and a high Return on Capital Employed, alongside a solid dividend yield and substantial institutional holdings.
Is Johnson & Johnson technically bullish or bearish?
As of July 24, 2025, Johnson & Johnson's technical trend is bullish, supported by positive MACD and moving averages, despite mixed signals from Dow Theory and OBV, and while it has underperformed the S&P 500 recently, it has outperformed year-to-date.
Is Johnson & Johnson overvalued or undervalued?
As of July 16, 2025, Johnson & Johnson's valuation has shifted from very attractive to attractive, with a current P/E ratio of 23, outperforming the S&P 500 year-to-date with a 20.43% return, but lagging behind over the past 3 and 5 years.
Is Johnson & Johnson technically bullish or bearish?
As of June 20, 2025, Johnson & Johnson's technical trend has shifted to bearish, supported by bearish signals from the MACD, KST, and daily moving averages, while the Bollinger Bands indicate a mildly bearish sentiment amidst a consolidation phase.
Is Johnson & Johnson overvalued or undervalued?
As of May 16, 2025, Johnson & Johnson is considered very attractive and undervalued, with a P/E ratio of 23, an EV to EBITDA of 16.16, and a return on equity of 25.13%, positioning it favorably compared to peers despite recent underperformance relative to the S&P 500.
Who are in the management team of Johnson & Johnson?
As of March 2022, Johnson & Johnson's management team includes Chairman and CEO Alex Gorsky and Lead Independent Director Anne Mulcahy, along with Independent Directors Dr. Mary Beckerle, Mr. D. Scott Davis, Mr. Ian Davis, and Dr. Jennifer Doudna.
What does Johnson & Johnson do?
Johnson & Johnson is a large-cap holding company focused on healthcare products, including pharmaceuticals and biotechnology, with recent net sales of $21.9 billion and a market cap of $440.9 billion. Key financial metrics include a P/E ratio of 23.00 and a dividend yield of 2.96%.
How big is Johnson & Johnson?
As of Jun 18, Johnson & Johnson has a market capitalization of $440.9 billion, with net sales of $89.3 billion and a net profit of $21.8 billion for the latest four quarters. The balance sheet shows shareholder's funds of $71.5 billion and total assets of $180.1 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
